About the Role
TigaTx, a Boston-based startup, is seeking a highly motivated, detail-oriented, proactive Senior Research Associate/Associate Scientist to join our team. The successful candidate will support the development of IgA-based antibody therapeutics to help unleash the tumor killing power of neutrophils by testing and executing protein and cell-based immunoassays. The ideal candidate will be highly organized, efficient, and careful in their approach to science with excellent interpersonal skills and should enjoy collaborating as a team player in a fast-paced, exciting, ever-changing startup environment.
Key Responsibilities
Develop and execute in vitro and ex vivo cell-based functional and molecular assays
Perform cell culture, cell isolation and characterization from human blood and mouse tissues
Analyze data and present work regularly to the scientific team
Maintain detailed laboratory notebooks, write SOPs, and carefully document experimental design and results in a well-maintained laboratory notebook
Requirements
BA or MS in Biology, Immunology, or similar with at least 3 years of relevant laboratory experience
Strong experience with cell biology and molecular techniques including multi-parameter flow cytometry, luminescence/fluorescence/absorbance plate-based assays such as ELISA/ MSD/Luminex, and qPCR
Expertise in tissue culture of adherent and suspension cells and proficiency with transfections and viral transductions
Experience with cell-based functional assays and/or immunophenotyping strongly desired
Ability to establish robust, reproducible experiments and troubleshoot assays
Eagerness to learn and implement new assays and protocols for a variety of in vitro experiments
Excellent oral and written communication skills
Outstanding organizational skills with strong attention to detail and an ability to work under pressure to meet critical timelines
Ability to thrive in a highly collaborative, fast-paced, team-oriented environment with colleagues from diverse disciplines
Must be eligible to work in the United States without sponsorship
About TigaTx
TigaTx is developing engineered IgA monoclonal antibodies to unleash the tumor killing power of neutrophils, thereby providing a new class of medicines for the treatment of cancer patients.
Neutrophils have emerged as playing an increasing role in cancer and being an important component of the tumor microenvironment. Neutrophils, including immunosuppressive neutrophils (aka PMN-MDSC), express FcαRI (CD89), the main receptor for the IgA Fc region. Opsonization of tumor cells by IgA will lead to IgA binding to the FcαRI on neutrophils, thus converting neutrophils into potent tumor killer cells.
The company was founded in 2018 based on the groundbreaking scientific work of Dr. Leusen’s lab at the University Medical Center Utrecht in the Netherlands.
TigaTx is developing its preclinical programs in stealth mode after securing substantial seed financing from an international consortium of top-tier investors.